Trial Name: GlaxoSmithKline
An Open-Label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-Line Treatment of Chemonaive Subjects with Extensive Small Cell Lung Cancer
Trial Description:
This study is being conducted to evaluate the effectiveness and safety of treating patients with small cell lung cancer with a combination of weekly hycamtin and carboplatin.
Patients:
- At least 18 years old
- Diagnosed with extensive small cell lung cancer
- No brain metastases
- No previous chemotherapy for small cell lung cancer
- Lab tests, a current physical exam and medical history must meet study specific criteria
This is a brief overview of this clinical trial and only selected eligibility criteria are listed.
If you are interested in receiving more information to see if you are eligible to participate in this study, please contact:
Mercy General Hospital, Rhoda Pineda at (916) 453-4651, or e-mail rpineda@chw.edu
Mercy San Juan Medical Center, Margaret Murphy at (916) 537-5109, or e-mail margaret.murphy2@chw.edu
